deltatrials
Completed PHASE3 INTERVENTIONAL 2-arm NCT03006770

Efficacy, Tolerability and Safety of Intramuscular Injections of PLX PAD for the Treatment of Subjects With Critical Limb Ischemia (CLI) With Minor Tissue Loss Who Are Unsuitable for Revascularization

Sponsor: Pluristem Ltd.

Conditions Critical Limb Ischemia (CLI)
Interventions PLX-PAD Placebo
Updated 25 times since 2017 Last updated: Aug 29, 2024 Started: May 22, 2017 Primary completion: Mar 3, 2021 Completion: Apr 20, 2022
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT03006770, this PHASE3 trial focuses on Critical Limb Ischemia (CLI) and remains completed. Sponsored by Pluristem Ltd., it has been updated 25 times since 2017, reflecting substantial change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

~Jan 2017 – ~Feb 2017 · 31 days · monthly snapshot~Feb 2017 – ~Jun 2017 · 4 months · monthly snapshot~Jun 2017 – ~Jul 2017 · 30 days · monthly snapshot~Jul 2017 – ~Sep 2017 · 2 months · monthly snapshot~Sep 2017 – ~Oct 2017 · 30 days · monthly snapshot~Oct 2017 – ~Dec 2017 · 2 months · monthly snapshot~Dec 2017 – ~Jan 2018 · 31 days · monthly snapshot~Jan 2018 – ~Mar 2018 · 59 days · monthly snapshot~Mar 2018 – ~Jun 2018 · 3 months · monthly snapshot~Jun 2018 – ~Jul 2018 · 30 days · monthly snapshot~Jul 2018 – ~Sep 2018 · 2 months · monthly snapshot~Sep 2018 – ~Oct 2018 · 30 days · monthly snapshot~Oct 2018 – ~Jan 2019 · 3 months · monthly snapshot~Jan 2019 – ~Apr 2019 · 3 months · monthly snapshot~Apr 2019 – ~May 2019 · 30 days · monthly snapshot~May 2019 – ~Oct 2019 · 5 months · monthly snapshot~Oct 2019 – ~Dec 2019 · 2 months · monthly snapshot~Dec 2019 – ~Aug 2020 · 8 months · monthly snapshot~Aug 2020 – ~Sep 2020 · 31 days · monthly snapshot~Sep 2020 – ~Jan 2021 · 4 months · monthly snapshot~Jan 2021 – ~Feb 2023 · 25 months · monthly snapshot~Feb 2023 – ~Jul 2024 · 17 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Sep 2025 · 12 months · monthly snapshot~Sep 2025 – present · 10 months · monthly snapshot

Change History

25 versions recorded

  1. Sep 2025 — Present [monthly]

    Completed PHASE3

  2. Sep 2024 — Sep 2025 [monthly]

    Completed PHASE3

    Status: Unknown → Completed

  3. Jul 2024 — Sep 2024 [monthly]

    Unknown PHASE3

    Status: Unknown Status → Unknown

  4. Feb 2023 — Jul 2024 [monthly]

    Unknown Status PHASE3

    Status: Active Not Recruiting → Unknown Status

  5. Jan 2021 — Feb 2023 [monthly]

    Active Not Recruiting PHASE3

    Status: Recruiting → Active Not Recruiting

▶ Show 20 earlier versions

  1. Sep 2020 — Jan 2021 [monthly]

    Recruiting PHASE3

  2. Aug 2020 — Sep 2020 [monthly]

    Recruiting PHASE3

  3. Dec 2019 — Aug 2020 [monthly]

    Recruiting PHASE3

  4. Oct 2019 — Dec 2019 [monthly]

    Recruiting PHASE3

  5. May 2019 — Oct 2019 [monthly]

    Recruiting PHASE3

  6. Apr 2019 — May 2019 [monthly]

    Recruiting PHASE3

  7. Jan 2019 — Apr 2019 [monthly]

    Recruiting PHASE3

  8. Oct 2018 — Jan 2019 [monthly]

    Recruiting PHASE3

  9. Sep 2018 — Oct 2018 [monthly]

    Recruiting PHASE3

  10. Jul 2018 — Sep 2018 [monthly]

    Recruiting PHASE3

  11. Jun 2018 — Jul 2018 [monthly]

    Recruiting PHASE3

  12. Mar 2018 — Jun 2018 [monthly]

    Recruiting PHASE3

  13. Jan 2018 — Mar 2018 [monthly]

    Recruiting PHASE3

  14. Dec 2017 — Jan 2018 [monthly]

    Recruiting PHASE3

  15. Oct 2017 — Dec 2017 [monthly]

    Recruiting PHASE3

  16. Sep 2017 — Oct 2017 [monthly]

    Recruiting PHASE3

  17. Jul 2017 — Sep 2017 [monthly]

    Recruiting PHASE3

  18. Jun 2017 — Jul 2017 [monthly]

    Recruiting PHASE3

    Status: Not Yet Recruiting → Recruiting

  19. Feb 2017 — Jun 2017 [monthly]

    Not Yet Recruiting PHASE3

  20. Jan 2017 — Feb 2017 [monthly]

    Not Yet Recruiting PHASE3

    First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Pluristem Ltd.
Data source: Pluristem Ltd.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Ashkelon, Israel , Austin, United States , Bad Krozingen, Germany , Berlin, Germany , Boston, United States , Bristol, United Kingdom , Budapest, Hungary , Burgas, Bulgaria , Dallas, United States , Dresden, Germany and 37 more locations